Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Li, Li xia ^a,b   Zhang, Yan ling ^c,d   Zhou, Ling ^a   Ke, Miao la ^a   Chen, Jie min ^a   Fu, Xiang ^a   Ye, Chun ling ^d   Wu, Jiang xue ^a   Liu, Ran yi ^a   Huang, Wenlin ^a,e  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d JINAN UNIVERSITY   (China)

^e Science Park   (China)

Author keywords

Adenovirus (Ad) vector; Endostatin; Gastric cancer; Oncolytic adenovirus (Ad); Viral gene therapy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AD ENDO; ADENOVIRUS VECTOR; CD34 ANTIGEN; ENDOSTATIN; HEXON PROTEIN; LONTUCIREV; PROTEIN; PROTEIN P14; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BALB/C NUDE MOUSE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CAPILLARY DENSITY; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TARGET CELL DESTRUCTION; TRANSGENE; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; WESTERN BLOTTING;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSTATINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIRUSES; RECOMBINATION, GENETIC; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VIRAL PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885358393     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-257     Document Type: Article

References (56)

1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009, 125:666-673. 10.1002/ijc.24290, 19382179.
2. Hu XT, He C. Recent progress in the study of methylated tumor suppressor genes in gastric cancer. Chin J Cancer 2013, 32:31-41. 10.5732/cjc.011.10175, 22059906.
3. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907. 10.1158/1055-9965.EPI-10-0437, 20647400.
4. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008, 9:279-287. 10.1016/S1470-2045(08)70072-X, 18308253.
5. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev 2010, 36:384-392. 10.1016/j.ctrv.2010.01.005, 20176443.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Eng J Med 1971, 285:1182-1186.
7. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
8. Folkman J. Angiogenesis. Annu Rev Med 2006, 57:1-18. 10.1146/annurev.med.57.121304.131306, 16409133.
9. Samaranayake H, Maatta AM, Pikkarainen J, Yla-Herttuala S. Future prospects and challenges of antiangiogenic cancer gene therapy. Human Gene Ther 2010, 21:381-396.
10. Cao Y. Angiogenesis: what can it offer for future medicine?. Exp Cell Res 2010, 316:1304-1308. 10.1016/j.yexcr.2010.02.031, 20206162.
11. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739. 10.1038/nrc905, 12360276.
12. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 2008, 100:113-131.
13. Clamp AR, Jayson GC. The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 2005, 93:967-972. 10.1038/sj.bjc.6602820, 2361682, 16234821.
14. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285. 10.1016/S0092-8674(00)81848-6, 9008168.
15. Peng F, Chen M. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia. Chin J Cancer 2010, 29:715-720. 10.5732/cjc.010.10010, 20663317.
16. Wu JX, Xu BL, Huang WL. [Research advancement of endogenous angiogenesis inhibitors]. Chin J Cancer (Ai Zheng) 2005, 24:376-384.
17. Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002, 20:3772-3784. 10.1200/JCO.2002.02.082, 12228197.
18. Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS. Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 2011, 12:1101-1116. 10.2174/138920111796117300, 3114256, 21470139.
19. Zheng MJ. Endostatin derivative angiogenesis inhibitors. Chin Med J (Engl) 2009, 122:1947-1951.
20. Wen QL, Meng MB, Yang B, Tu LL, Jia L, Zhou L, Xu Y, Lu Y. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 2009, 100:1510-1519. 10.1111/j.1349-7006.2009.01193.x, 19459845.
21. Zhao P, Luo R, Wu J, Xie F, Li H, Xiao X, Fu L, Zhu X, Liu R, Zhu Y, et al. E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases. J Cell Mol Med 2010, 14:381-391.
22. Liang Z, Wu J, Huang J, Tan W, Ke M, Liu R, Huang B, Xiao X, Zhao P, Huang W. Bioactivity and stability analysis of endostatin purified from fermentation supernatant of 293 cells transfected with Ad/rhEndo. Protein Expr Purif 2007, 56:205-211. 10.1016/j.pep.2007.08.008, 17933553.
23. Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH, Zeng YX, Huang W. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer 2006, 118:2064-2071. 10.1002/ijc.21585, 16287067.
24. Li L, Huang JL, Liu QC, Wu PH, Liu RY, Zeng YX, Huang WL. Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. World J Gastroenterol 2004, 10:1867-1871.
25. Huang BJ, Liu RY, Huang JL, Liang ZH, Gao GF, Wu JX, Huang W. Long-Term toxicity studies in Canine of E10A, an adenoviral vector for human endostatin gene. Human Gene Ther 2007, 18:207-221.
26. Li HL, Li S, Shao JY, Lin XB, Cao Y, Jiang WQ, Liu RY, Zhao P, Zhu XF, Zeng MS, et al. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene therapy 2008, 15:247-256. 10.1038/sj.gt.3303038, 18097470.
27. Lin X, Huang H, Li S, Li H, Li Y, Cao Y, Zhang D, Xia Y, Guo Y, Huang W, Jiang W. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007, 6:648-653. 10.4161/cbt.6.5.4004, 17426445.
28. Hallden G, Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets 2012, 16:945-958. 10.1517/14728222.2012.712962, 22880939.
29. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007, 7:133-139. 10.2174/156800907780058862, 17346104.
30. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006, 16:879-886. 10.1038/sj.cr.7310108, 17102812.
31. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376. 10.1126/science.274.5286.373, 8832876.
32. Barranco SC, Townsend CM, Casartelli C, Macik BG, Burger NL, Boerwinkle WR, Gourley WK. Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res 1983, 43:1703-1709.
33. Siddiqui KM, Chopra DP. Primary and long term epithelial cell cultures from human fetal normal colonic mucosa. In vitro 1984, 20:859-868. 10.1007/BF02619632, 6519668.
34. Baffa R, Negrini M, Schichman SA, Huebner K, Croce CM. Involvement of the ALL-1 gene in a solid tumor. Proc Natl Acad Sci U S A 1995, 92:4922-4926. 10.1073/pnas.92.11.4922, 41819, 7761425.
35. Lin CH, Fu ZM, Liu YL, Yang JL, Xu JF, Chen QS, Chen HM. Investigation of SGC-7901 cell line established from human gastric carcinoma cells. Chin Med J (Engl) 1984, 97:831-834.
36. Liu RY, Luo HL, Peng JL, Cai TY, Zhang CQ, Wu PH, Huang WL, Zeng YX. [Growth Inhibition and Mechanisms of E1B-Deleted Adenovirus on Nasopharyngeal Carcinoma CNE-2 Cells]. Chin J Cancer Biother 2002, 9:6-9.
37. Liu RY, Peng JL, Li YQ, Zhou L, Lin HX, Luo HL, Huang BJ, Huang W. Tumor-Specific Cytolysis, Caused by an E1B55K-Attenuated Adenovirus in Nasopharyngeal Carcinoma, can be Augmented by Chemotherapeutic Agent Cisplatin. Anat Rec (Hoboken) 2013, Oct. doi: 10.1002/ar.22813. [Epub ahead of print].
38. Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK, et al. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene 2011, 30:4814-4823. 10.1038/onc.2011.189, 3165083, 21625209.
39. Liu RY, Zhu YH, Zhou L, Zhao P, Li HL, Zhu LC, Han HY, Lin HX, Kang L, Wu JX, Huang W. Adenovirus-mediated delivery of interferon-gamma gene inhibits the growth of nasopharyngeal carcinoma. J Transl Med 2012, 10:256. 10.1186/1479-5876-10-256, 3573957, 23272637.
40. Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin 2004, 25:146-147.
41. Lee B, Choi J, Kim J, Kim JH, Joo CH, Cho YK, Kim YK, Lee H. Oncolysis of human gastric cancers by an E1B 55 kDa-deleted YKL-1 adenovirus. Cancer Lett 2002, 185:225-233. 10.1016/S0304-3835(02)00279-3, 12169397.
42. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Human Mutation 2003, 21:258-270. 10.1002/humu.10180, 12619111.
43. Bellini MF, Cadamuro AC, Succi M, Proenca MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012, 2012:891961. 3420349, 22919278.
44. Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, Yuasa Y. Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int J Cancer 2000, 87:654-658. 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P, 10925358.
45. Tahara T, Shibata T, Arisawa T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Yonemura J, Maeda Y, Maruyama N, et al. CpG island promoter methylation (CIHM) status of tumor suppressor genes correlates with morphological appearances of gastric cancer. Anticancer Res 2010, 30:239-244.
46. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Chin J Cancer (Ai Zheng) 2004, 23:1666-1670.
47. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nature Biotechnol 2012, 30:658-670.
48. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887. 10.1016/j.cell.2011.08.039, 21925313.
49. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Rev Clin Oncol 2011, 8:210-221.
50. Yan L. Molecular targeted agents-where we are and where we are going. Chin J Cancer 2013, 32:225-232. 10.5732/cjc.013.10051, 23642906.
51. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Biotechnol 1999, 17:343-348.
52. He GA, Xue G, Xiao L, Wu JX, Xu BL, Huang JL, Liang ZH, Xiao X, Huang BJ, Liu RY, Huang W. Dynamic distribution and expression in vivo of human endostatin gene delivered by adenoviral vector. Life Sci 2005, 77:1331-1340. 10.1016/j.lfs.2005.01.023, 15936041.
53. Adhim Z, Lin X, Huang W, Morishita N, Nakamura T, Yasui H, Otsuki N, Shigemura K, Fujisawa M, Nibu K, Shirakawa T. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Ther 2012, 19:144-152. 10.1038/cgt.2011.79, 22116375.
54. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, Libutti SK. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000, 60:1503-1506. 2247479, 10749112.
55. Flint S, Enquist L, Racaniello V, Skalka M. Principles of Virology: molecular biology, pathogenesis, and control of animal viruses 2004, Washington, DC: ASM Press, 2.
56. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Human Gene Ther 2005, 16:1016-1027.